Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44020   clinical trials with a EudraCT protocol, of which   7318   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001883-48
    Sponsor's Protocol Code Number:D933SC00001
    National Competent Authority:Poland - Office for Medicinal Products
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2019-01-04
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPoland - Office for Medicinal Products
    A.2EudraCT number2018-001883-48
    A.3Full title of the trial
    Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
    Wieloośrodkowe, globalne, randomizowane badanie fazy III prowadzone metodą otwartej próby oceniające leczenie pierwszego rzutu z zastosowaniem durwalumabu w skojarzeniu z chemioterapią standardową, durwalumabu w skojarzeniu z tremelimumabem i chemioterapią standardową oraz samej chemioterapii standardowej u pacjentów z nieoperacyjnym miejscowo zaawansowanym lub przerzutowym rakiem urotelialnym
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Advanced Urothelial
    Bladder Cancer
    Badanie oceniające zastosowanie durwalumabu w skojarzeniu z chemioterapią standardową, durwalumabu w skojarzeniu z tremelimumabem i chemioterapią standardową oraz samej chemioterapii standardowej u pacjentów zaawansowanym lub przerzutowym rakiem urotelialnym
    A.3.2Name or abbreviated title of the trial where available
    Nile
    Nile
    A.4.1Sponsor's protocol code numberD933SC00001
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03682068
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstrazeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca Clinical
    B.5.2Functional name of contact pointClinical Trial Transparency
    B.5.3 Address:
    B.5.3.1Street Address15185
    B.5.3.2Town/ citySodertalje
    B.5.3.3Post codeSE 151 85
    B.5.3.4CountrySweden
    B.5.6E-mailclinicaltrialtransparency@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namedurvalumab
    D.3.2Product code MEDI4736
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDurvalumab
    D.3.9.1CAS number 1428935-60-7
    D.3.9.2Current sponsor codeMEDI4736
    D.3.9.3Other descriptive nameMEDI4736
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametremelimumab
    D.3.2Product code MEDI1123
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTremelimumab
    D.3.9.1CAS number 745013-59-6
    D.3.9.2Current sponsor codeMEDI1123
    D.3.9.3Other descriptive nameMEDI1123
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
    Pacjenci z nieoperacyjnym miejscowo zaawansowanym lub przerzutowym rakiem urotelialnym
    E.1.1.1Medical condition in easily understood language
    Advanced urothelial bladder cancer for patients who cannot undergo surgery. Cancer arising in the urinary bladder or in other urinary tract sites such as the renal pelvis, ureters and urethra
    Zaawansowany rak pęcherza moczowego u pacjentów, którzy nie mogą być operowani; powstający w pęcherzu moczowym lub w innych miejscach układu moczowego jak miedniczki nerkowe, moczowód, cewka moczowa
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10005003
    E.1.2Term Bladder cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of durvalumab + SoC combination therapy versus SoC in terms of OS in patients with unresectable locally advanced or metastatic UC and high PD-L1 expression.

    To assess the efficacy of durvalumab and tremelimumab + SoC combination therapy versus SoC in terms of OS in patients with unresectable locally advanced or metastatic UC and high PD-L1 expression.
    Ocena skuteczności terapii łączonej durwalumab +terapia standardowa w porównaniu do terapii standardowej pod względem przeżycia całkowitego (OS) u pacjentów z nieoperacyjnym miejscowo zaawansowanym lub przerzutowym rakiem urotelialnym i wysoką ekspresją PD-L1.

    Ocena skuteczności terapii łączonej durwalumab i tremelimumab +terapia standardowa w porównaniu do terapii standardowej pod względem przeżycia całkowitego (OS) u pacjentów z nieoperacyjnym miejscowo zaawansowanym lub przerzutowym rakiem urotelialnym i wysoką ekspresją PD-L1.
    E.2.2Secondary objectives of the trial
    To assess the efficacy in patients in different treatment arms

    -To assess disease-related symptoms, safety, physical functioning, and other health related quality of life in patients in different treatment arms
    Ocena skuteczności u pacjentów w różnych ramionach terapeutycznych

    Ocena objawów związanych z chorobą, bezpieczeństwa, funkcjonowania fizycznego i innych parametrów związanych z jakością życia u pacjentów z różnych ramion terapeutycznych
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra)

    -Patients who have not been previously treated with first-line chemotherapy. Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant treatment for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy [for chemoradiation and adjuvant treatment] or >12 months from the last surgery [for neoadjuvant treatment].

    -At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.

    - World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment

    -Adequate organ and marrow function as defined in the protocol

    - Life expectancy ≥12 weeks in the opinion of the investigator

    -Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients.
    •Osoby z histologicznie lub cytologicznie potwierdzonym rakiem przejściowokomórkowym (w badaniu histologicznym komórki nabłonka przejściowego oraz mieszane komórki nabłonka przejściowego i inne) nabłonka urotelialnego (w tym miedniczki nerkowej, moczowodów, pęcherza moczowego i cewki moczowej), który jest nieoperacyjny, miejscowo zaawansowany lub przerzutowy;
    •Osoby, które nie były wcześniej leczone chemioterapią pierwszego rzutu. Pacjenci, u których zastosowano w przeszłości radykalną chemioradioterapię, leczenie wspomagające lub neoadiuwantowe z powodu miejscowo zaawansowanego nowotworu, pod warunkiem, że progresja do nowotworu miejscowo zaawansowanego lub przerzutowego wystąpiła w ciągu >12 miesięcy od ostatniego leczenia [w przypadku chemioradioterapii i leczenia wspomagającego] lub >12 miesięcy od ostatniej operacji [w przypadku leczenia neoadiuwantowego].)
    •Co najmniej jedna zmiana, która nie była wcześniej naświetlana i która została sklasyfikowana jako zmiana docelowa wg kryteriów RECIST 1.1 podczas oceny wyjściowej.
    •Stan sprawności wg skali Światowej Organizacji Zdrowia (WHO)/Eastern Cooperative Oncology Group (ECOG) 0 lub 1 w chwili kwalifikacji do udziału w badaniu.
    •Wydolna czynność narządów i szpiku kostnego, jak określana w protokole;
    •Oczekiwany czas przeżycia ≥12 tygodni w ocenie badacza;
    •Udokumentowany stan po menopauzie lub ujemny wynik testu ciążowego z moczu lub surowicy w przypadku pacjentek przed menopauzą.
    E.4Principal exclusion criteria
    - Prior exposure to immune-mediated therapy (with exclusion of Bacillus Calmette Guerin), including but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD L1, or anti-PD-L2 antibodies, except therapeutic anticancer vaccines, which are permitted. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.

    - No severe concomitant condition that requires immunosuppression medication

    - Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis

    - Patients who may be eligible for or are being considered for radical resection during the course of the study.

    - Any medical contraindications to platinum (cisplatin or carboplatin) based doublet chemotherapy and/or known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
    •Wcześniejsza ekspozycja na leczenie immunologiczne (z wyjątkiem BCG), w tym m.in. inne przeciwciała anty-CTLA-4, anty-PD-1, anty-PD-L1 lub anty-PD-L2, z wyłączeniem leczniczych szczepionek przeciwnowotworowych, których stosowanie jest dozwolone. Wcześniejsza miejscowa immunoterapia lub chemioterapia dopęcherzowa jest dozwolona, jeśli zakończyła się co najmniej 28 dni przed rozpoczęciem badanego leczenia.
    •Brak poważnych choroby współistniejących, wymagających leczenia immunologiczne
    •Nieleczone przerzuty do ośrodkowego układu nerwowego (OUN) i/lub nowotworowe zapalenie opon mózgowo-rdzeniowych
    •Pacjenci, którzy mogą kwalifikować się do cystektomii radykalnej lub rozważa się u nich przeprowadzenie tego zabiegu w trakcie badania.
    •Jakiekolwiek przeciwwskazania medyczne do stosowania dwulekowej chemioterapii na bazie platyny (cisplatyny lub karboplatyny) lub stwierdzona alergia lub nadwrażliwość na którykolwiek z badanych leków lub substancji pomocniczych badanych leków .
    E.5 End points
    E.5.1Primary end point(s)
    - Overall Survival (OS)
    •przeżycie całkowite (OS)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Assessments for overall survival will be made periodically until the end of study.
    Ocena przeżycia całkowitego będzie przeprowadzana okresowo do końca badania
    E.5.2Secondary end point(s)
    - Progression Free Survival (PFS)
    - Progression Free Survival (PFS)
    - Overall Survival (OS)
    - Alive and Progression Free Patients at 12 Months (APF12)
    - Overall Response Rate (ORR)
    - Disease Control Rate (DCR)
    - Duration of Response (DoR)
    - Time from Randomization to Second Progression PFS (PFS2)
    - Safety
    - Disease related symptoms
    •czas przeżycia bez progresji choroby (PFS);
    • przeżycie całkowite (OS)
    •odsetek pacjentów żyjących bez progresji choroby po 12 miesiącach od randomizacji (APF12);
    •odsetek odpowiedzi obiektywnych (ORR);
    •odsetek kontroli choroby (DCR);
    •czas trwania odpowiedzi (DoR);
    •czas od randomizacji do drugiej progresji (PFS2)
    •bezpieczeństwo
    •objawy związane z chorobą
    E.5.2.1Timepoint(s) of evaluation of this end point
    Assessments will be made periodically until the end of study.
    Oceny będą przeprowadzane okresowo aż do końca badania.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA49
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Philippines
    Taiwan
    Australia
    Brazil
    Canada
    China
    India
    Israel
    Japan
    Korea, Republic of
    Russian Federation
    Thailand
    Turkey
    United States
    Viet Nam
    Bulgaria
    Czechia
    Hungary
    Italy
    Poland
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS

    In the event that a roll-over or safety extension study is available at the time of the final data cut-off and database closure, patients currently receiving treatment with durvalumab may be transitioned to such a study, and the current study would reach its end. The roll-over or safety extension study would ensure treatment continuation with visit assessments per its protocol. Any patient who would be proposed to move to such a study would be given a new informed consent form (ICF).
    LVLS

    Jeżeli w chwili finalnego odcięcia danych i zamknięcia bazy danych prowadzone będzie kontynuacyjne lub przedłużone badanie oceniające bezpieczeństwo (pbob), pacjenci otrzymujący leczenie MEDI4736 mogą zostać przeniesieni do tego typu badania, a ten projekt zakończy się. Badanie kontynuacyjne / pbob zapewnią dalsze leczenie i ocenę zgodną z danym protokołem. Każdy z uczestników, po zaproponowaniu przeniesienia do takiego badania otrzyma nowy formularz informacji i zgody pacjenta.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years8
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 517
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 775
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    A legal representative may provide consent on behalf of a subject incapable of giving consent personally, where permitted by local regulations.
    Jeżeli pacjent nie jest zdolny do wyrażenia pisemnej świadomej zgody osobiście, może ona zostać wyrażona przez zgody jego przedstawiciela ustawowego
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state130
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 351
    F.4.2.2In the whole clinical trial 1292
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients who continue to receive benefit from their assigned treatment at the end of study may continue to receive their assigned treatment for as long as they and their physician feel they are gaining clinical benefit.
    Pacjenci odnoszący korzyść z przypisanego leczenia pod koniec badania, mogą kontynuować przyjmowanie przypisanego leczenia tak długo, jak długo w opinii lekarza pacjenci odnoszą korzyść kliniczną.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-01-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-11-08
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA